Phase I trial of a bivalent gangliosides vaccine in combination with β-glucanB. H. Kushner et. al. 2017.
Relapse of high-risk neuroblastoma (HR-NB) has long been viewed as tantamount to eventual death from progressive disease (PD) or toxicity.1 We hypothesize that active humoral immunity could maintain second or subsequent remission even among these ultra-high-risk patients. This curative approach star...Continue reading on PMC